Analyst Price Target is $3.00
▲ +934.48% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Check-Cap in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 934.48% upside from the last price of $0.29.
Current Consensus is
The current consensus among 2 investment analysts is to buy stock in Check-Cap. This Buy consensus rating has held steady for over two years.
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.